Home
About Telix Clinical Trials
Trial Screener
Expanded access programs
Research Areas
Trial Search

Search for:

Home
About Telix Clinical Trials
Trial Screener
Expanded access programs
Research Areas
Trial Search

Explore our
Research Areas

Prostate Cancer
Kidney Cancer
Brain Cancers
Musculoskeletal Cancers

About
Trials
- Trial Search
- Active Trials
Disease Areas

©2025 Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia. The Telix Pharmaceuticals®, Telix Group company, and Telix product and trial names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Illuccix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved in multiple markets globally including in the U.S., Australia and Europe. Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. FDA. Scintimun® (technetium-99m (⁹⁹mTc) besilesomab) is approved in Europe and Mexico. Telix’s miniaturized surgical gamma probe, SENSEI®, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. Registrations vary country to country. Refer to your local approved label or regulatory authority status for full information. No other Telix drug or device has received marketing authorization in any jurisdiction.

Privacy Policy
Terms of Use
Cookies Policy